In a systematic review and meta-analysis by Bronsveld et al. focusing on insulin analogs and breast cancer risk, glargine was identified as the only clinically available insulin analog showing enhanced proliferative potential in breast cancer cell lines. This evidence concerns the gene INS and breast carcinoma.